#United States #biotechnology #Carlsbad #Tyra Biosciences #Habib Dable

Tyra Biosciences Welcomes Habib Dable to Its Board

On April 17, 2026, Tyra Biosciences, Inc., a leading company in the clinical-stage biotechnology sector, made a groundbreaking announcement about the addition of Habib Dable to its Board of Directors. With over three decades of extensive experience in the global biopharmaceutical industry, Dable is anticipated to play a pivotal role in guiding the company's strategic direction and commercial growth.

Bringing Expertise to Tyra Biosciences

Habib Dable is renowned for his expertise in building blockbuster pharmaceutical franchises and facilitating transformative company growth. His previous role as President and CEO of Acceleron Pharma Inc. saw the company achieve significant milestones, culminating in its acquisition by Merck in 2021. This experience positions him uniquely to assist Tyra as it navigates its next growth phase.

Todd Harris, CEO of Tyra Biosciences, remarked on the significance of Dable’s appointment: "As TYRA advances into its next phase of growth, Habib brings the kind of experience and strategic insight that will be critical at the Board level." His proven track record in global product launches will undoubtedly be instrumental as Tyra aims to develop and commercialize dabogratinib for various critical indications.

Strategic Vision and Focus on FGFR Biology

Dable's insights into market trends and product positioning are expected to help Tyra unlock the full potential of FGFR3 inhibition. The company is committed to delivering significant therapies to patients affected by various oncological conditions. Emphasizing the urgency in tackling FGFR3, he stated, "FGFR3 represents one of the most compelling and difficult-to-drug targets in oncology and genetic conditions."

Dable's vision aligns with Tyra’s strategic initiatives, famously labeled as the "3x3" strategy, which aims to build a broad, multi-indication franchise. This focus is believed to have the potential to create substantial long-term commercial impact for the company.

A Wealth of Experience in Biopharmaceuticals

Dable's robust background includes pivotal roles at Bayer AG, where he spent an impressive 22 years. During his tenure there, he made significant contributions across various therapeutic areas such as ophthalmology, neurology, hematology, and cardiology, even overseeing the global launch of EYLEA®. This diverse experience complements his consulting roles at multiple biotech firms, showcasing his versatility and strategic acumen in the pharmaceutical industry.

In addition to his new role at Tyra Biosciences, Dable is involved with several boards, including Spyglass Pharma and Relay Therapeutics. His academic credentials, including a B.B.A. and M.B.A. from the University of New Brunswick, further substantiate his expertise as a leader in the sector.

Transition and Leadership Changes

Tyra Biosciences also announced that Gilla Kaplan will conclude her Board service at this year’s annual stockholder meeting. Kaplan has played a significant role in shaping Tyra's early phase and growth trajectory. The company expressed its gratitude for her contributions during this foundational period.

What Lies Ahead for Tyra Biosciences

The future is looking promising for Tyra Biosciences under the newly appointed leadership of Habib Dable. The integration of his expertise into the company’s operations indicates a decisive step towards innovative developments in drug candidates tailored towards oncology, particularly targeting FGFR pathways. As the company continues to develop its precision medicine platform, the strategic insights from Dable will likely play a crucial role in enhancing Tyra's standing within the biotechnology landscape.

Tyra's commitment to creating next-generation precision medicines aims to address significant gaps in healthcare, ultimately bringing therapies that could redefine treatment paradigms for patients suffering from complex conditions. With robust leadership and a clear vision, Tyra Biosciences is poised for a transformative chapter in its evolution as a pioneering biopharmaceutical entity.